1
|
Maillart E, Labauge P, Cohen M, Maarouf A, Vukusic S, Donzé C, Gallien P, De Sèze J, Bourre B, Moreau T, Louapre C, Mayran P, Bieuvelet S, Vallée M, Bertillot F, Klaeylé L, Argoud AL, Zinaï S, Tourbah A. MSCopilot, a new multiple sclerosis self-assessment digital solution: results of a comparative study versus standard tests. Eur J Neurol 2019; 27:429-436. [PMID: 31538396 DOI: 10.1111/ene.14091] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2019] [Revised: 07/24/2019] [Accepted: 09/09/2019] [Indexed: 01/09/2023]
Abstract
BACKGROUND AND PURPOSE Assessing patients' disability in multiple sclerosis (MS) requires time-consuming batteries of hospital tests. MSCopilot is a software medical device for the self-assessment of patients with MS (PwMS), combining four tests: walking, dexterity, cognition and low contrast vision. The objective was to validate MSCopilot versus the Multiple Sclerosis Functional Composite (MSFC). METHODS This multicentre, open-label, randomized, controlled, crossover study enrolled 141 PwMS and 76 healthy controls (HCs). All participants performed MSCopilot and MSFC tests at day 0. To assess reproducibility, 46 PwMS performed the same tests at day 30 ± 3. The primary end-point was the validation of MSCopilot versus MSFC for the identification of PwMS against HCs, quantified using the area under the curve (AUC). The main secondary end-point was the correlation of MSCopilot z-scores with MSFC z-scores. RESULTS In all, 116 PwMS and 69 HCs were analysed. The primary end-point was achieved: MSCopilot performance was non-inferior to that of MSFC (AUC 0.92 and 0.89 respectively; P = 0.3). MSCopilot and MSFC discriminated PwMS and HCs with 81% and 76% sensitivity and 82% and 88% specificity respectively. Digital and standard test scores were highly correlated (r = 0.81; P < 0.001). The test-retest study demonstrated the good reproducibility of MSCopilot. CONCLUSION This study confirms the reliability of MSCopilot and its usability in clinical practice for the monitoring of MS-related disability.
Collapse
Affiliation(s)
- E Maillart
- Department of Neurology, Pitié Salpêtrière Hospital, Paris, France
| | - P Labauge
- Department of Neurology, Montpellier University Hospital, Montpellier, France
| | - M Cohen
- Department of Neurology, Nice University Hospital, Nice, France
| | - A Maarouf
- CNRS, CRMBM, APHM, Aix-Marseille University, Marseille, France.,Pole de Neurosciences Cliniques, Marseille, France
| | - S Vukusic
- Department of Neurology, Hospices Civils de Lyon, Bron, France.,INSERM 1028 et CNRS UMR 5292, University Lyon 1, Lyon, France
| | - C Donzé
- Department of Physical and Rehabilitation Medicine, Groupe Hospitalier de l'Institut Catholique de Lille, Lille, France
| | - P Gallien
- Physical Rehabilitation Medicine, Pole Saint Helier, Rennes, France
| | - J De Sèze
- Department of Neurology, Hôpital Civil, Strasbourg University, Strasbourg, France
| | - B Bourre
- Department of Neurology, Rouen University Hospital, Rouen, France
| | - T Moreau
- Department of Neurology, Dijon University Hospital, Dijon, France
| | - C Louapre
- Department of Neurology, Pitié Salpêtrière Hospital, Paris, France
| | | | - S Bieuvelet
- Ad Scientiam, Brain and Spine Institute (ICM), Pitié Salpêtrière Hospital, Paris, France
| | - M Vallée
- Ad Scientiam, Brain and Spine Institute (ICM), Pitié Salpêtrière Hospital, Paris, France
| | - F Bertillot
- Ad Scientiam, Brain and Spine Institute (ICM), Pitié Salpêtrière Hospital, Paris, France
| | - L Klaeylé
- Ad Scientiam, Brain and Spine Institute (ICM), Pitié Salpêtrière Hospital, Paris, France
| | - A-L Argoud
- Ad Scientiam, Brain and Spine Institute (ICM), Pitié Salpêtrière Hospital, Paris, France
| | - S Zinaï
- Ad Scientiam, Brain and Spine Institute (ICM), Pitié Salpêtrière Hospital, Paris, France
| | - A Tourbah
- Department of Neurology, Reims University Hospital, URCA, Reims, France.,LPN EA, 2027 Paris 8 University, Saint-Denis, France.,Service de Neurologie, Hôpitaux universitaires paris-Ile-de-France Ouest, APHP, Université Versailles-Saint Quentin en Yvelines, Paris Saclay, France
| |
Collapse
|
2
|
Deccache A, Didier A, Mayran P, Jeziorski A, Raherison C. [Asthma: Adapting the therapeutic follow-up according to the medical and psychosocial profiles]. Rev Mal Respir 2018; 35:313-323. [PMID: 29602481 DOI: 10.1016/j.rmr.2017.06.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Accepted: 06/17/2017] [Indexed: 10/17/2022]
Abstract
INTRODUCTION This work is based on the data of REALISE™, a survey conducted among 8000 European patients to identify the profiles of adult asthma patients and how these are linked with treatment adherence behaviors. METHODS A cluster analysis was performed by combining data in three ways: control of asthma, attitude towards the disease, compliance with treatment. A multidisciplinary group analyzed the results for the 1024 French survey respondents. RESULTS Four patient profiles were identified: "rather confident" (28% of patients), rather young patients with a low level of concern about their asthma. "Rather committed" (23%) patients considering themselves to be mostly healthy, reporting better therapeutic declared. "Rather questing" (26%), patients poorly controlled, seeking to manage their asthma themselves. "Rather concerned" profile (23%), a bit older, with poor clinical control, considering their asthma to be severe. CONCLUSIONS Cluster analysis provides a multidimensional approach to understand the therapeutic behavior of the different patient profiles better and so adjust communication by and education of healthcare professionals.
Collapse
Affiliation(s)
- A Deccache
- Université catholique de Louvain, 1200 Bruxelles, Belgique.
| | - A Didier
- Pôle des voies respiratoires, CHU de Toulouse, 31059 Toulouse, France
| | - P Mayran
- Éditions PM Santé, Garches, 92380 France
| | - A Jeziorski
- Laboratoires Mundipharma, 75015 Paris, France
| | - C Raherison
- U1219, service des maladies respiratoires, université de Bordeaux, CHU de Bordeaux, 33076 Bordeaux, France
| |
Collapse
|